AEON Biopharma

AEON

Biotechnology · Healthcare

Exchange

New York Stock Exchange Arca

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Winston Score History

The full picture

AEON Biopharma is a small biotechnology company focused on developing a drug called ABP-450, which is a form of botulinum toxin — the same type of substance used in Botox. The company is working to get this drug approved for medical conditions like cervical dystonia (a painful neck muscle disorder) and chronic migraine, targeting patients who need prescription treatments rather than cosmetic procedures.

AEON does not yet sell any products, so it currently generates no revenue. It operates primarily in the United States and funds its research through capital raises, which is typical for early-stage biotech companies. The company's financial metrics reflect heavy spending with no income, as shown by its deeply negative returns. The key growth driver is winning FDA approval for ABP-450, but the main risk is that clinical trials could fail or face delays, and the company competes against well-established botulinum toxin products already on the market from much larger companies.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+96.2% YoY

YoY Growth Rate

EPS growth accelerating

Insider Activity

72.6%ownership

Insiders own a meaningful stake in the company

Cash Runway

~3 months

$3M cash & investments

Short runway — potential dilution ahead through share issuance

Cash watch

AEON Biopharma has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

—

Data not available

Profit after running costs

Operating Margin

N/A

—

Data not available

Return on the money invested

ROCE

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

—

Data not available

Profit growth

EPS YoY

N/A

Data not available

How steady the profit is

EPS Consistency

5/8 quarters

Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

—

Data not available

Covers its interest

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial